Treatment with elagolix was associated with sustained reduction in average monthly dysmenorrhea and non-menstrual pelvic pain through a 12-month treatment period.
A flexible extended regimen of 20 mg ethinylestradiol and 3 mg drospirenone (FlexibleMIB) was shown to be superior to placebo for reducing endometriosis-related pain.
At 3 months, significantly more women receiving both doses of elagolix had reductions in dysmenorrhea and nonmenstrual pelvic pain compared with those receiving placebo.
Women with chronic pelvic pain had greater connectivity in "pain" regions of the brain, regardless of presence of endometriosis.
Clinical Pain Advisor Articles
- Opioid Use in Chronic Low Back Pain: A Population Study
- Risks Associated With Co-Administration of Aspirin and Other NSAIDs
- FDA Approves Aimovig for Migraine Prevention
- Stages of Low Back Pain Have Specific Sets of Clinical Indicators
- First Non-Opioid Drug Approved for Managing Opioid Withdrawal Symptoms
- Effect of Prescription Drug Monitoring Programs on Fatal, Nonfatal Drug Overdoses
- Standardized SCS Workflow May Effectively Alleviate Failed Back Surgery Syndrome-Related Pain
- Marijuana Legalization and Opioid Prescribing Rates
- Medical Marijuana Users More Likely to Use Prescription Drugs for Medical, Nonmedical Purposes
- Interbrain Coupling During Handholding Associated With Analgesia, Empathy
- Opioid-Related Adverse Drug Events Associated With Worse Patient, Cost Outcomes
- Education Plus Exercise, Single Corticosteroid Injection Effective in Long Term for Gluteal Tendinopathy
- Detox vs Medication-Assisted Treatment for Opioid Use Disorder in Pregnancy: Expert Roundtable
- Naloxone Training Beneficial for PA Students
- Supervised Injection Sites Hailed as the Latest Strategy to Fight the Opioid Crisis